Form 4: Orchestra BioMed CEO's Tax Withholding on RSU Vesting

Orchestra BioMed Holdings, Inc. CEO David P. Hochman reported a disposition of 32,438 shares for tax withholding related to RSU vesting.

Summary

• David P. Hochman, Chief Executive Officer and Chairperson of Orchestra BioMed Holdings, Inc., reported a transaction on March 25, 2026.
• The transaction involved the disposition of 32,438 shares of Common Stock at a price of $4.57 per share.
• This disposition was solely for the purpose of satisfying tax withholding obligations in connection with the vesting of restricted stock units (RSUs).
• No shares were sold in the open market as a result of this transaction.
• Following the transaction, Mr. Hochman directly owns 1,054,029 shares and indirectly owns 448,622 shares through various trusts.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a routine, non-discretionary transaction related to executive compensation, indicating RSU vesting and continued substantial insider ownership, which is generally a positive signal.

Positives

• The transaction was a non-market sale for tax withholding purposes, indicating RSU vesting rather than a discretionary sale by the insider.
• The insider continues to hold a significant number of shares, both directly (1,054,029) and indirectly (448,622), demonstrating continued alignment with shareholder interests.

Negatives

• A reduction in direct beneficial ownership by 32,438 shares, even for tax purposes, slightly decreases the insider's direct stake.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Form 4 filings detailing tax-related dispositions upon RSU vesting are common for executives in publicly traded companies across various industries. This type of transaction is a standard mechanism for managing equity compensation and typically does not reflect a change in management's fundamental view of the company's prospects, unlike open market sales.

Comparison to Industry Standards

• This type of tax withholding transaction is a standard practice for equity compensation across industries, including biotech and medical device companies like Orchestra BioMed.
• It aligns with common executive compensation structures seen at peers such as Medtronic (MDT) or Boston Scientific (BSX) where RSU vesting often triggers similar tax-related share dispositions.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a non-market tax withholding, but confirms RSU vesting.
• Employees: No direct impact.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction for tax withholding purposes related to RSU vesting. It does not signal a change in the company's fundamentals or management's outlook, nor does it represent a discretionary sale. The CEO retains significant direct and indirect ownership, suggesting continued alignment. Therefore, the filing itself does not warrant a change in investment thesis, supporting a 'hold' recommendation.

Keywords

Orchestra BioMed Holdings, OBIO, David P. Hochman, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Beneficial Ownership